loading page

Outcomes after transvenous defibrillator implantation in cardiac sarcoidosis: a systematic review
  • +3
  • Ahmed Taha,
  • Omar Assaf,
  • Asgher Champsi,
  • Ashwin Roy,
  • Ramesh Nadarajah,
  • Peysh Patel A
Ahmed Taha
Leeds General Infirmary
Author Profile
Omar Assaf
Blackpool Victoria Hospital
Author Profile
Asgher Champsi
New Cross Hospital
Author Profile
Ashwin Roy
Queen Elizabeth Hospital Birmingham
Author Profile
Ramesh Nadarajah
Leeds General Infirmary
Author Profile
Peysh Patel A
Queen Elizabeth Hospital Birmingham

Corresponding Author:[email protected]

Author Profile

Abstract

Introduction Sarcoidosis is a systemic inflammatory disorder associated with ventricular arrhythmias (VAs) and sudden death in the context of cardiac involvement. Established guidelines advocate implantable cardioverter-defibrillator (ICD) implantation in specific subcohorts, but there is a paucity of data on outcomes. Methods and Results We conducted a systematic review of published literature to assess outcomes in patients with cardiac sarcoidosis (CS) treated with ICD. Observational studies of patients with definite or probable CS and ICD implantation were identified from multiple databases from inception to 21 st May 2021. Outcomes of interest included appropriate and inappropriate ICD therapies in addition to all-cause mortality. Study quality was assessed individually using the Newcastle Ottawa Scale (NOS). Eight studies were identified comprising 530 patients, with follow-up period of 24 to 66 months (weighted average 40 months). Mean age was 53.9 years with ejection fraction of 41.3%. Overall incidence of appropriate therapy, reported in all studies, was 39% during follow-up. Left ventricular systolic dysfunction (LVSD) with ejection fraction < 40% was a predictor of appropriate therapy in the majority of studies, as were sustained VAs during electrophysiological testing (EP) in one study. Inappropriate therapy was documented in six studies and primarily driven by atrial arrhythmias. All-cause mortality was reported in six studies, with incidence of 6.0% over a median follow-up period of 42 months. Only three studies achieved good quality in the comparability domain of NOS. Conclusions Appropriate ICD therapy in patients with CS is commonly associated with LVSD, which may act as a surrogate for scar burden. The utility of EP testing in this setting remains unclear.